Citigroup Inc Alpha Teknova, Inc. Transaction History

Citigroup Inc

$163 Billion
Q4 2024

A detailed history of Citigroup Inc transactions in Alpha Teknova, Inc. stock. As of the latest transaction made, Citigroup Inc holds 12,836 shares of TKNO stock, worth $106,282. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,836

Previous 45,055 71.51%

Holding current value

$106,282

Previous $218,000 50.92%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	SELL	$4.55 - $8.97 $146,596 - $289,004	-32,219 Reduced 71.51%	12,836 $107,000
Q3 2024 Nov 12, 2024	BUY	$1.2 - $5.17 $53,725 - $231,466	44,771 Added 15764.44%	45,055 $218,000
Q2 2024 Aug 12, 2024	SELL	$1.29 - $2.81 $9,220 - $20,085	-7,148 Reduced 96.18%	284 $0
Q1 2024 May 10, 2024	BUY	$2.41 - $3.88 $10,589 - $17,048	4,394 Added 144.63%	7,432 $19,000
Q4 2023 Feb 09, 2024	BUY	$1.85 - $3.73 $5,614 - $11,320	3,035 Added 101166.67%	3,038 $11,000
Q2 2023 Aug 10, 2023	BUY	$1.8 - $3.98 $1 - $3	1 Added 50.0%	3 $0
Q1 2023 May 11, 2023	SELL	$2.74 - $6.25 $123 - $281	-45 Reduced 95.74%	2 $0
Q4 2022 Feb 09, 2023	SELL	$3.23 - $5.64 $1,227 - $2,143	-380 Reduced 88.99%	47 $0
Q3 2022 Nov 10, 2022	SELL	$3.34 - $9.2 $1,616 - $4,452	-484 Reduced 53.13%	427 $1,000
Q2 2022 Aug 10, 2022	BUY	$6.39 - $16.24 $230 - $584	36 Added 4.11%	911 $8,000
Q1 2022 May 12, 2022	SELL	$12.79 - $21.64 $21,781 - $36,852	-1,703 Reduced 66.06%	875 $12,000
Q4 2021 Feb 10, 2022	BUY	$17.49 - $26.72 $29,610 - $45,236	1,693 Added 191.3%	2,578 $53,000
Q3 2021 Nov 10, 2021	BUY	$17.47 - $27.49 $15,460 - $24,328	885 New	885 $22,000

Others Institutions Holding TKNO

# of Institutions

Shares Held

6.54M

Call Options Held

Put Options Held

View Full List

About Alpha Teknova, Inc.

Ticker TKNO
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 28,080,500
Market Cap $233M
Description
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; ...

More about TKNO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account